HAART treatment with free provided medications for people living with HIV in Huzhou, China

• We have provided HAART drug combinations to PLWH for AIDS treatment in Huzhou, China. The free provided drugs included 3TC+EFV+TDF and drugs paid by patients included BIC+FTC+TAF. Free and paid drug combinations similarly increase CD4+ T-cell count and decrease VL. For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province. Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment. Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl ( p =0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml ( p =0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations. The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Virology Plus
Published
2024-09-20
DOI
https://doi.org/10.1016/j.jcvp.2024.100191
Citations
1
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HAART treatment with free provided medications for people living with HIV in Huzhou, China

Meiling Xu, Qingqiu Zeng, Xiaofeng Li, Wei Zhang et al.
1 citations
Journal of Clinical Virology Plus
HIV/AIDS drug development and treatment
0.39
article

HAART treatment with free provided medications for people living with HIV in Huzhou, China

Meiling Xu, Qingqiu Zeng, Xiaofeng Li, Wei Zhang, Yan Zhang, Weihong Wang, Bin Shen, Kefeng Qin, Zhaowei Tong
article en
1 citations

Abstract

• We have provided HAART drug combinations to PLWH for AIDS treatment in Huzhou, China. The free provided drugs included 3TC+EFV+TDF and drugs paid by patients included BIC+FTC+TAF. Free and paid drug combinations similarly increase CD4+ T-cell count and decrease VL. For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province. Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment. Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl ( p =0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count>500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml ( p =0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations. The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.

Journal of Clinical Virology PlusVol. 4(4)
Huzhou Normal University (CN), Huzhou Central Hospital (CN)
Zhejiang Province Public Welfare Technology Application Research Project, Basic Public Welfare Research Program of Zhejiang Province
Openalex Percentile: Top 37%
HIV/AIDS drug development and treatment
0.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.